Stock Events

Stock Events

Cell Source 

$0.5171
6
-$0.37-41.89% Thursday 18:08

Statistics

Day High
0.8899
Day Low
0.648
52W High
2.25
52W Low
0.25
Volume
1,300
Avg. Volume
2,483
Mkt Cap
35.13M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

2NovExpected
Q3 2020
Q1 2021
Q2 2021
Q2 2021
Q3 2021
Q1 2022
Q3 2022
-0.06
-0.04
-0.02
0
Expected EPS
0
Actual EPS
-0.05

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-6.15MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Cell Source's cell therapy innovations.
Novartis
NVS
Mkt Cap292.35B
Novartis offers CAR-T cell therapies, directly competing with Cell Source's cell therapy approaches for cancer.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the CAR-T therapy space, similar to Cell Source's offerings.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on gene therapy, which could serve as an alternative to Cell Source's therapeutic strategies.
Adaptive Biotechnologies
ADPT
Mkt Cap4.02B
Adaptive Biotechnologies focuses on immune-driven medicine, potentially competing with Cell Source's immune system modulation therapies.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics is involved in allogeneic CAR-T cell therapies, a direct competitor to Cell Source's personalized cell therapies.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is developing programmed cellular immunotherapies, competing in the same space as Cell Source.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is engaged in various biopharmaceutical innovations, including cell therapy, posing a broad competitive landscape to Cell Source.

About

Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Show more...
CEO
Itamar Shimrat
Employees
1
Country
United States
ISIN
US15114L1044

Listings

OTC Link
US
CLCS

0 Comments

Share your thoughts

FAQ

What is Cell Source stock price today?▼
The current price of CLCS is $0.52 USD — it has decreased by -41.89% in the past 24 hours. Watch Cell Source stock price performance more closely on the chart.
What is Cell Source stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Cell Source stocks are traded under the ticker CLCS.
Is Cell Source stock price growing?▼
CLCS stock has fallen by -10.69% compared to the previous week, the month change is a -41.57% fall, over the last year Cell Source has showed a +26.12% increase.
What is Cell Source market cap?▼
Today Cell Source has the market capitalization of 35.13M
What were Cell Source earnings last quarter?▼
CLCS earnings for the last quarter are -0.05 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cell Source revenue for the last year?▼
Cell Source revenue for the last year amounts to 0 USD.
What is Cell Source net income for the last year?▼
CLCS net income for the last year is -6.15M USD.
How many employees does Cell Source have?▼
As of September 04, 2026, the company has 1 employees.
In which sector is Cell Source located?▼
Cell Source operates in the Health & Wellness sector.
When did Cell Source complete a stock split?▼
Cell Source has not had any recent stock splits.
Where is Cell Source headquartered?▼
Cell Source is headquartered in New York City, United States.